Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 10/20 | 1.00 |
| ▸ | CLK1 | P49759 | 9/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15961987 | 0.85 | DYRK1A (0.74) | DYRK1ADYRK1BCLK1HSD17B1CA2 | |
| SCHEMBL2194399 | 0.83 | DYRK1A (0.71) | DYRK1ADYRK1BCLK1HSD17B1CA2 | |
| SCHEMBL6840172 | 0.81 | DYRK1A (0.69) | DYRK1ADYRK1BCLK1HSD17B1LMNA | |
| SCHEMBL7075713 | 0.81 | DYRK1A (0.69) | DYRK1ADYRK1BCLK1HSD17B1CA2 | |
| SCHEMBL3641925 | 0.81 | DYRK1A (0.68) | DYRK1ADYRK1BCLK1HSD17B1CA2 | |
| SCHEMBL13036384 | 0.80 | DYRK1A (0.67) | DYRK1ADYRK1BCLK1HSD17B1LMNA | |
| SCHEMBL13036381 | 0.80 | CLK1 (0.67) | DYRK1ADYRK1BCLK1HSD17B1LMNA | |
| SCHEMBL17988510 | 0.80 | CLK1 (0.67) | DYRK1ADYRK1BCLK1LMNAKDM4E | |
| SCHEMBL121775 | 0.80 | LMNA (0.69) | DYRK1ADYRK1BCLK1LMNABCL2L1 | |
| SCHEMBL9612673 | 0.79 | DYRK1A (0.65) | DYRK1ADYRK1BCLK1HSD17B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6900216-B2 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1268489-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | Knoll GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001068653-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | KNOLL GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | DYRK1A 2939/4885DYRK1B 3081/4885CLK1 1590/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | DYRK1A 4499/4885DYRK1B 4663/4885CLK1 4222/4885 |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | GPR119, HTR3B, HTR2B | DYRK1A 2096/4885DYRK1B 1989/4885CLK1 3230/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | DYRK1A 4499/4885DYRK1B 4663/4885CLK1 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.